{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:40:52Z","timestamp":1791614452933,"version":"4.3.4"},"reference-count":67,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"JSPS KAKENHI","award":["17K08452"],"award-info":[{"award-number":["17K08452"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medicine"],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Several smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes are widely used. We evaluated the adverse events related to smoking cessation treatments and electronic cigarettes in the US Food and Drug Administration Adverse Event Reporting System database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed reports of adverse events associated with smoking cessation treatment and electronic cigarettes terms dated between January 2004 and December 2016. We used the reporting odds ratio with 95% confidence intervals to detect a signal for each adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 8,867,135 reports in the Food and Drug Administration Adverse Event Reporting System database were analyzed. The numbers of adverse events for nicotine replacement therapy (transdermal, buccal, oral, and respiratory administration) were 1673, 1016, 425, and 56, respectively. Nicotine replacement therapy (transdermal, buccal, and oral) demonstrated adverse events of nausea, nicotine dependence, and dizziness. For nicotine (transdermal) exposure, the top 5 adverse events reported were nausea (149 cases, reporting odds ratio: 2.28 (95% confidence interval: 1.92\u20132.69)), dizziness (132 cases, reporting odds ratio: 3.04 (95% confidence interval: 2.54\u20133.63)), application site erythema (108 cases, reporting odds ratio: 32.52 (95% confidence interval: 26.74\u201339.55)), headache (98 cases, reporting odds ratio: 1.84 (95% confidence interval: 1.50\u20132.25)), and dyspnea (94 cases, reporting odds ratio: 1.93 (95% confidence interval: 1.57\u20132.38)). Many cases of improper use of nicotine replacement therapies were reported. Nausea, depression, abnormal dreams, insomnia, and other adverse events were reported for varenicline. Insomnia, rash, anxiety, and dizziness were reported for bupropion. We observed electronic cigarettes\u2013related adverse events such as dizziness, dyspnea, nausea, heart rate increased, and tremor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings suggest that an association exists between nicotine-related adverse events and nicotine replacement therapy. Healthcare professionals should closely monitor smokers trying to quit nicotine use for the misuse of nicotine replacement therapy. These findings may be informative to healthcare professionals in order to improve the management of smoking cessation treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2050312118777953","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:25:21Z","timestamp":1526948721000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":27,"title":["Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004\u22122016"],"prefix":"10.1177","volume":"6","author":[{"given":"Yumi","family":"Motooka","sequence":"first","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Matsui","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M","family":"Slaton","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryogo","family":"Umetsu","sequence":"additional","affiliation":[{"name":"Micron Technology, Inc., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiho","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Naganuma","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Sasaoka","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Hatahira","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Laboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-5522","authenticated-orcid":false,"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"bibr1-2050312118777953","unstructured":"World Health Organization. Tobacco Fact sheet, http:\/\/www.who.int\/mediacentre\/factsheets\/fs339\/en\/ (2017 accessed 16 February 2018)."},{"key":"bibr2-2050312118777953","unstructured":"Eriksen M, Mackay J, Schluger N, et al. The tobacco atlas. 5th ed. American Cancer Society, World Lung Foundation, http:\/\/3pk43x313ggr4cy0lh3tctjh.wpengine.netdna-cdn.com\/wp-content\/uploads\/2015\/03\/TA5_2015_WEB.pdf (2015 accessed 16 February 2018)."},{"key":"bibr3-2050312118777953","volume-title":"Treating tobacco use and dependence","author":"Fiore MC","year":"2008"},{"key":"bibr4-2050312118777953","unstructured":"Wong P, Aveyard P. Combination treatment in smoking cessation\u2014is there an optimal regimen? Touch Briefings, http:\/\/www.touchophthalmology.com\/sites\/www.touchoncology.com\/files\/migrated\/articles_pdfs\/aveyard.pdf (2008 accessed 16 February 2018)."},{"key":"bibr5-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2004.07.004"},{"key":"bibr6-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1038\/30001"},{"key":"bibr7-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009329.pub2"},{"key":"bibr8-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.17.2083"},{"key":"bibr9-2050312118777953","unstructured":"American Cancer Society. American Cancer Society position statement on electronic cigarettes, https:\/\/www.cancer.org\/healthy\/stay-away-from-tobacco\/e-cigarette-position-statement.html (accessed 21 April 2018)."},{"key":"bibr10-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.17.2033"},{"key":"bibr11-2050312118777953","unstructured":"Pfizer Labs. Division of Pfizer Inc. CHANTIX\u00ae (varenicline) Tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021928s012s013lbl.pdf (accessed 21 April 2018)."},{"key":"bibr12-2050312118777953","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0022-3565(24)38905-0","volume":"295","author":"Slemmer JE","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr13-2050312118777953","unstructured":"GlaxoSmithKline. Zyban (bupropion hydrochloride) Sustained Release Tablets. Product Information, https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Zyban\/pdf\/ZYBAN-PI-MG.PDF (2006 accessed 16 February 2018)."},{"key":"bibr14-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1445-7"},{"key":"bibr15-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0693-0"},{"key":"bibr16-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.007667"},{"key":"bibr17-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000107"},{"key":"bibr18-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02751.x"},{"key":"bibr19-2050312118777953","unstructured":"American Lung Association. E-cigarettes and lung health, http:\/\/www.lung.org\/stop-smoking\/smoking-facts\/e-cigarettes-and-lung-health.html (2016 accessed 16 February 2018)."},{"key":"bibr20-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2015-052235"},{"key":"bibr21-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2016.10.036"},{"key":"bibr22-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/nts145"},{"key":"bibr23-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2014.10.009"},{"key":"bibr24-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2016.06.002"},{"key":"bibr25-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"bibr26-2050312118777953","unstructured":"US and Food Drug Administration. FDA adverse event reporting system, https:\/\/open.fda.gov\/data\/faers\/ (2014 accessed 16 February 2018)."},{"key":"bibr27-2050312118777953","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). INTECH 2012: 265\u2013302, https:\/\/www.intechopen.com\/books\/data-mining-applications-in-engineering-and-medicine\/data-mining-techniques-in-pharmacovigilance-analysis-of-the-publicly-accessible-fda-adverse-event-re","DOI":"10.5772\/50095"},{"key":"bibr28-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-015-0015-6."},{"key":"bibr29-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b14-00191"},{"key":"bibr30-2050312118777953","unstructured":"MedDRA, https:\/\/www.meddra.org (accessed 16 February 2018)."},{"key":"bibr31-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"bibr32-2050312118777953","unstructured":"International Council for Harmonization. Introductory guide MedDRA version 19.0, https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_19_0_english.pdf (accessed 21 April 2018)."},{"key":"bibr33-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-1809-8"},{"key":"bibr34-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.61.5.743"},{"key":"bibr35-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-111314-033712"},{"key":"bibr36-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110218"},{"key":"bibr37-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2856"},{"key":"bibr38-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027016"},{"key":"bibr39-2050312118777953","first-page":"19","volume":"10","author":"Penberthy JK","year":"2016","journal-title":"Subst Abuse"},{"key":"bibr40-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.8.1433"},{"key":"bibr41-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30272-0"},{"key":"bibr42-2050312118777953","unstructured":"U.S. Food & Drug Administration. FDA drug safety communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings [news release], http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm532221.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery (accessed 16 February 2018)."},{"key":"bibr43-2050312118777953","doi-asserted-by":"publisher","DOI":"10.7196\/samj.6887"},{"key":"bibr44-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-0288"},{"key":"bibr45-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1136\/tc.2009.033498"},{"key":"bibr46-2050312118777953","first-page":"841","volume":"69","author":"Czoga\u0142a J","year":"2012","journal-title":"Przegl Lek"},{"key":"bibr47-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.03791.x"},{"key":"bibr48-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/nts103"},{"key":"bibr49-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2011.572213"},{"key":"bibr50-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2013-051474"},{"key":"bibr51-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1136\/tc.2009.031567"},{"key":"bibr52-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1177\/2042098614524430"},{"key":"bibr53-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008545"},{"key":"bibr54-2050312118777953","unstructured":"Science Lab.com. Material safety data sheet propylene glycol MSDS. https:\/\/www.sciencelab.com\/msds.php?msdsId=9927239 (2013 accessed 16 February 2018)."},{"key":"bibr55-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/0038-092X(81)90033-5"},{"key":"bibr56-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1334"},{"key":"bibr57-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2013.09.034"},{"key":"bibr58-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2443"},{"key":"bibr59-2050312118777953","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph110504965"},{"key":"bibr60-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0481-x"},{"key":"bibr61-2050312118777953","first-page":"99","volume":"21","author":"Polosa R","year":"2016","journal-title":"Discov Med"},{"key":"bibr62-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066317"},{"key":"bibr63-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61842-5"},{"key":"bibr64-2050312118777953","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.yrtph.2016.09.014","volume":"81","author":"Haziza C","year":"2016","journal-title":"Regul Toxicol Pharm"},{"key":"bibr65-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1201\/b13973"},{"key":"bibr66-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2013-051479"},{"key":"bibr67-2050312118777953","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2015-052626"}],"container-title":["SAGE Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050312118777953","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050312118777953","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050312118777953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:14:33Z","timestamp":1777594473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050312118777953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":67,"alternative-id":["10.1177\/2050312118777953"],"URL":"https:\/\/doi.org\/10.1177\/2050312118777953","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"article-number":"2050312118777953"}}